Bruker Co. (NASDAQ:BRKR) Receives $79.36 Average Price Target from Analysts

Bruker Co. (NASDAQ:BRKR - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eleven brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $79.36.

Several equities research analysts recently commented on BRKR shares. Citigroup cut their price target on Bruker from $80.00 to $75.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. Barclays dropped their price target on shares of Bruker from $75.00 to $69.00 and set an "overweight" rating for the company in a research note on Wednesday, November 6th. Wolfe Research lowered shares of Bruker from an "outperform" rating to a "peer perform" rating in a research report on Monday, September 30th. TD Cowen lowered their price objective on Bruker from $72.00 to $70.00 and set a "hold" rating for the company in a research report on Wednesday, November 6th. Finally, Wells Fargo & Company reduced their target price on Bruker from $78.00 to $75.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 6th.

Insider Transactions at Bruker

In related news, CEO Frank H. Laukien bought 100,000 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was purchased at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the purchase, the chief executive officer now directly owns 38,439,563 shares of the company's stock, valued at $1,927,359,688.82. This trade represents a 0.26 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 28.30% of the company's stock.

Hedge Funds Weigh In On Bruker

Institutional investors and hedge funds have recently made changes to their positions in the stock. First Horizon Advisors Inc. raised its holdings in Bruker by 120.4% in the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company's stock valued at $25,000 after acquiring an additional 218 shares in the last quarter. True Wealth Design LLC raised its holdings in shares of Bruker by 4,636.4% in the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company's stock valued at $36,000 after purchasing an additional 510 shares in the last quarter. UMB Bank n.a. raised its holdings in shares of Bruker by 115.3% in the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company's stock valued at $46,000 after purchasing an additional 354 shares in the last quarter. Gordian Capital Singapore Pte Ltd purchased a new stake in shares of Bruker during the 2nd quarter worth $52,000. Finally, GAMMA Investing LLC increased its holdings in Bruker by 81.0% in the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company's stock valued at $60,000 after buying an additional 388 shares during the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Price Performance

NASDAQ BRKR traded down $0.82 during mid-day trading on Tuesday, hitting $57.55. The stock had a trading volume of 1,133,615 shares, compared to its average volume of 1,646,186. Bruker has a twelve month low of $48.07 and a twelve month high of $94.86. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. The firm's 50 day moving average is $60.45 and its 200 day moving average is $63.79. The stock has a market capitalization of $8.72 billion, a price-to-earnings ratio of 27.67, a PEG ratio of 3.92 and a beta of 1.18.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a return on equity of 21.52% and a net margin of 9.41%. The business had revenue of $864.40 million during the quarter, compared to analysts' expectations of $866.46 million. During the same period in the prior year, the business posted $0.74 earnings per share. The business's quarterly revenue was up 16.4% on a year-over-year basis. Equities research analysts forecast that Bruker will post 2.4 earnings per share for the current fiscal year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Monday, December 2nd will be given a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.35%. The ex-dividend date is Monday, December 2nd. Bruker's dividend payout ratio is currently 9.62%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.